SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about outcome of board meeting

26 Sep 2025 Evaluate
Glenmark Pharmaceuticals has informed that the Board of Directors of the Company, at its meeting held today, Friday, 26th September, 2025, have approved the following agendas: The Board of Directors of the Company, has considered and approved the Interim Dividend of Rs 2.50 per equity shares on face value of Re 1 per equity shares for the Financial Year 2025-26 amounting to Rs 705.50 millions. As intimated earlier on 22nd September 2025, the record date for the purpose of payment of dividend shall be Friday, 3rd October, 2025, and the interim dividend will be paid within 30 days from the date of the declaration.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

2364.35 -6.70 (-0.28%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×